QNEXA for Weight Loss in obesity – CONQUER study
QNEXA? Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities – VIVUS, Inc. (NASDAQ: VVUS) announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.